DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

Chao Zhang, Hong Lei Zhang, Meng Nan Han, Xue Li Yang, Chao Hong Pei, Zhi Dong Xu, Jie Du, Wei Li, Shengxi Chen

Research output: Contribution to journalArticle

Abstract

Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

Original languageEnglish (US)
Pages (from-to)1982-1989
Number of pages8
JournalRSC Advances
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2019

Fingerprint

Chemotherapy
Cisplatin
DNA
Nanoparticles
Toxicity
Molecules
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Zhang, C., Zhang, H. L., Han, M. N., Yang, X. L., Pei, C. H., Xu, Z. D., ... Chen, S. (2019). DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. RSC Advances, 9(4), 1982-1989. https://doi.org/10.1039/C8RA08735K

DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. / Zhang, Chao; Zhang, Hong Lei; Han, Meng Nan; Yang, Xue Li; Pei, Chao Hong; Xu, Zhi Dong; Du, Jie; Li, Wei; Chen, Shengxi.

In: RSC Advances, Vol. 9, No. 4, 01.01.2019, p. 1982-1989.

Research output: Contribution to journalArticle

Zhang, C, Zhang, HL, Han, MN, Yang, XL, Pei, CH, Xu, ZD, Du, J, Li, W & Chen, S 2019, 'DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy', RSC Advances, vol. 9, no. 4, pp. 1982-1989. https://doi.org/10.1039/C8RA08735K
Zhang, Chao ; Zhang, Hong Lei ; Han, Meng Nan ; Yang, Xue Li ; Pei, Chao Hong ; Xu, Zhi Dong ; Du, Jie ; Li, Wei ; Chen, Shengxi. / DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. In: RSC Advances. 2019 ; Vol. 9, No. 4. pp. 1982-1989.
@article{c3bfc0c058d14870bf386dc2d9442c29,
title = "DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy",
abstract = "Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57{\%} at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9{\%}, 33.3 μM).",
author = "Chao Zhang and Zhang, {Hong Lei} and Han, {Meng Nan} and Yang, {Xue Li} and Pei, {Chao Hong} and Xu, {Zhi Dong} and Jie Du and Wei Li and Shengxi Chen",
year = "2019",
month = "1",
day = "1",
doi = "10.1039/C8RA08735K",
language = "English (US)",
volume = "9",
pages = "1982--1989",
journal = "RSC Advances",
issn = "2046-2069",
publisher = "Royal Society of Chemistry",
number = "4",

}

TY - JOUR

T1 - DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

AU - Zhang, Chao

AU - Zhang, Hong Lei

AU - Han, Meng Nan

AU - Yang, Xue Li

AU - Pei, Chao Hong

AU - Xu, Zhi Dong

AU - Du, Jie

AU - Li, Wei

AU - Chen, Shengxi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

AB - Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

UR - http://www.scopus.com/inward/record.url?scp=85060297477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060297477&partnerID=8YFLogxK

U2 - 10.1039/C8RA08735K

DO - 10.1039/C8RA08735K

M3 - Article

VL - 9

SP - 1982

EP - 1989

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 4

ER -